Table 6.
Approved bispecific antibodies and chimeric antigen T-cell receptor therapy in multiple myeloma.
| Clinical trial | Number of patients | Treatment regimen | Median age (years) | Median follow up (months) | Progression-free survival (months) |
|---|---|---|---|---|---|
| CARTITUDE-1103 | 97 | Ciltacabtagene autoleucel | 61 | 27.7 | NR |
| KarMMa104 | 128 | Idecabtagene vivleucel | 61 | 15.4 | 8.8 |
| CARTITUDE-4105 | 419 | Ciltacabtagene autoleucel vs SOC | 61 | 15.9 | NR vs 11.8 |
| KarMMa-3106 | 386 | Idecabtegene vivleucel vs SOC | 63 | 18.6 | 13.3 vs 4.4 |
| MajesTEC-1107 | 125 | Teclistimab CD3/BCMA | 64 | 14.1 | 11.3 |
| MagnetisMM-3108 | 123 | Elranatamab CD3/BCMA | 68 | 14.7 | NR |
| MonumenTAL-1109 | 232 | Talquetamab CD3/GPRC5D | 62 | 11.7 | 7.5 |
Abbreviations: NR, not reached, SOC, standard of care, BCMA, B-cell maturation antigen, GPRC5D, G protein-coupled receptor family C group 5 member D.